George Scangos (via Getty Images)
October 6, 2020 09:15 AM EDTUpdated 10:38 AM
R&D
Coronavirus

GSK, Vir cleared to leap in­to PhI­II, an­gling for a spot in the Covid-19 an­ti­body race led by Lil­ly, Re­gen­eron

Amber Tong

Six months af­ter Glax­o­SmithK­line paid $250 mil­lion for a stake in Vir Biotech­nol­o­gy and a seat at the ta­ble de­vel­op­ing an­ti­bod­ies against Covid-19, it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times